Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims & Hers Health announced it may no ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as ...